


Docket No. 00-721-US
 Serial No.: 09/828,276

CLAIMS

1. (Previously presented) A compound of the formula:




R₁ and R₂ are each an amine group or an alkylamine group;
 further wherein R₃, R₄, and R₅ are each a hydrogen or a halogen;
 further wherein R₆ is an alkyl alcohol group or a carboxamido group;
 or a pharmaceutically acceptable salt thereof.


2. Cancelled.
 3. Cancelled.
 4. (Previously presented) The compound of Claim 1, wherein R₁ and R₂ each contain one to thirteen carbons.
 5. Cancelled.

Docket No. 00-721-US
 Serial No.: 09/828,276

6. (Previously presented) The compound of Claim 1, wherein the amine group is on a terminal carbon.
7. (Previously presented) The compound of Claim 1, wherein said halogen is selected from the group consisting of fluorine, chlorine and bromine.
8. (Previously presented) The compound of Claim 1, wherein R₆ is selected from the group consisting of methyl alcohol, ethyl alcohol, isopropyl alcohol and n-propyl alcohol.
9. (Original) The compound of Claim 1, wherein R₆ is a N-alkylcarboxamido group selected from the group consisting of N-methylcarboxamido, N-ethylcarboxamido, N-isopropylcarboxamido, and N-n-propylcarboxamido.
10. (Previously presented) A compound of the formula:




wherein R₁, R₂, are each:



R₃, R₄, and R₅ are each hydrogen;


and R₆ is:




; or a pharmaceutically acceptable salt thereof.

11. Cancelled.
12. Cancelled.
13. Cancelled.
14. Cancelled.
15. Cancelled.
16. Cancelled.
17. Cancelled.
18. Cancelled.
19. Cancelled.
20. Cancelled.
21. (Previously presented) The compound of Claim 1, wherein said amine group is selected from the group consisting of primary amine, secondary amine and tertiary amine.

22. (Previously presented) The compound of Claim 1, wherein R₁ and R₂ are each:



23. (Previously presented) A pharmaceutical composition for the treatment of hypertension comprising an effective amount of a compound of the formula:



wherein R₁ and R₂ are each an amino group or an alkylamine group;
 further wherein R₃, R₄, and R₅ are each a hydrogen or a halogen;
 further wherein R₆ is an alkyl alcohol group or a carboxamido group;
 or a pharmaceutically acceptable salt thereof;
 and a pharmaceutically acceptable carrier.

Docket No. 00-721-US
Serial No.: 09/828,276

24. (Previously presented) The pharmaceutical composition of Claim 23, wherein R₁ and R₂ each contain one to thirteen carbons.
25. (Previously presented) The pharmaceutical composition of Claim 23, wherein said amine group is selected from the group consisting of primary amine, secondary amine and tertiary amine.
26. (Previously presented) The pharmaceutical composition of Claim 23, wherein said amine group is on a terminal carbon.
27. (Previously presented) The pharmaceutical composition of Claim 23, wherein said halogen selected from the group consisting of fluorine, chlorine and bromine.
28. (Previously presented) The pharmaceutical composition of Claim 23, wherein said alkyl alcohol group is selected from the group consisting of methyl alcohol, ethyl alcohol, isopropyl alcohol and n-propyl alcohol.
29. (Previously presented) The pharmaceutical composition of Claim 23, wherein R₆ is a N-alkylcarboxamido group selected from the group consisting of N-methylcarboxamido, N-ethylcarboxamido, N-isopropylcarboxamido and N-n-propylcarboxamido.
30. (Previously presented) The pharmaceutical composition of Claim 23, wherein R₁ and R₂ are each:

